Constrained Peptide Drugs Market Size, Share & Trends Analysis Report by Peptide Type (Disulfide-Rich Peptides (DRPs) and Cyclic Peptides) and Potential Product (BT5528, Rusfertide (PTG-300), PN-943, PN-235, and Zilucoplan (RA101495)), Region And Segment Forecasts, 2023-2031

Report ID : 1944 | Published : 2023-08-01 | Pages: 180 | Format: PDF/EXCEL

The Global Constrained Peptide Drugs Market Size is predicted to witness a 31.56% CAGR during the forecast period for 2023-2031.

Constrained Peptide Drugs Market

Polypeptide chains with cyclic rings make up cyclic peptides. The ring structure can be created by joining the ends of the peptide together with an amide bond or another chemically stable bond such as lactone, ether, thioether, disulfide, and so on. Many biologically active cyclic peptides are produced through the process known as N-to-C (or head-to-tail) cyclization, which involves the production of amide bonds between the amino and carboxyl termini.

In clinical settings, a number of cyclic peptides from nature are employed. A variety of factors, such as an increase in the number of older individuals, an increase in the prevalence of chronic diseases, and a rise in patient knowledge of peptide therapies breakthroughs, are projected to drive the development of the market for peptide therapeutics.

The increase in product development and technical advancements is another prominent market trend that is projected to boost expansion in the future years. At first, COVID-19 had a significant effect on market expansion. For instance, according to a Frontiers article from May 2022, the pandemic led to the development of many peptide-based vaccines and medication candidates, which had a favourable impact on the management of COVID-19 infections. As a result, the pandemic greatly influenced the market's expansion. The market, however, is anticipated to have steady development during the projected period now that the epidemic has passed. 

Competitive Landscape:

Some of the major key players in the Constrained Peptide Drugs Market are:

 • Aileron Therapeutics, Inc.
• Bicycle Therapeutics plc
• Spexis AG
• Protagonist Therapeutics Inc.
• Santhera Pharmaceuticals
• Union Chimique Belge S.A. (UCB)
• Creative Peptides
• Biosynth (Pepscan)
• Pepticom Ltd.
• PeptiDream Inc.
• Bio-Synthesis Inc
• CPC Scientific Inc.
• Circle Pharma
• Zealand Pharma
• Chugai Pharmaceutical Co. Ltd.

Market Segmentation:

The Constrained Peptide Drugs market is segmented on the basis of Peptide Type and Potential Product. By Peptide Type, the market is segmented into Disulfide-Rich Peptides (DRPs) and Cyclic Peptides. On the basis of Potential Products, the market is segmented into BT5528, Rusfertide (PTG-300), PN-943, PN-235, and Zilucoplan (RA101495).

Based On Peptide Type, The Disulfide-Rich Peptides (Drps) Segment Is Accounted As A Noteworthy Contributor In The Constrained Peptide Drugs Market

The pipeline-restricted peptides with either few or no licenced medications for the condition are included in the disulfide-rich peptides (DRPs) category, which is predicted to dominate the worldwide constrained peptide pharmaceuticals market. A group of peptides known as DRPs have many intramolecular disulfide bonds, which give them exceptional structural stability and bioactive characteristics. Due to their distinctive disulfide link configuration, these peptides are also known as cysteine-rich or cystine-knot peptides.

The Zilucoplan (RA101495) Segment Witnessed Growth At A Rapid Rate

The Zilucoplan (RA101495) segment is projected to grow rapidly in the global constrained peptide drugs market. UCB Pharmaceuticals is creating Zilucoplan to treat myasthenia gravis (MG) and other complement-mediated diseases. An autoimmune condition called myasthenia gravis damages the neuromuscular junction and results in tiredness and muscle weakening. Zilucoplan is made to block the complement system's C5 protein, which is involved in inflammation and the immunological response.

The North America Constrained Peptide Drugs Market Holds A Significant Revenue Share In The Region

Due to the growing need for anti-cancer medications, the rising incidence of cardiovascular disorders and other diseases, as well as the high demand for peptide and anticoagulant drugs, North America is anticipated to hold a sizable share of the global market for these medications throughout the forecast period. Aspects such as the rising burden of cancer and the rising frequency of cardiovascular diseases are expected to increase demand for peptide and anticoagulant medications.

Constrained Peptide Drugs Market Report Scope:

Report Attribute

Specifications

Growth Rate CAGR

CAGR of 31.56 % from 2023 to 2031

Quantitative Units

Representation of revenue in US$ Million and CAGR from 2023 to 2031

Historic Year

2019 to 2022

Forecast Year

2023-2031

Report Coverage

The forecast of revenue, the position of the company, the competitive market structure, growth prospects, and trends

Segments Covered

By Peptide Type and Potential Product

Regional Scope

North America; Europe; Asia Pacific; Latin America; Middle East & Africa

Country Scope

U.S.; Canada; U.K.; Germany; China; India; Japan; Brazil; Mexico; The UK; France; Italy; Spain; China; Japan; India; South Korea; South East Asia; South Korea; South East Asia

Competitive Landscape

Aileron Therapeutics Inc., Bicycle Therapeutics plc, Spexis AG, Protagonist Therapeutics Inc., Santhera Pharmaceuticals, Union Chimique Belge S.A. (UCB), Creative Peptides, Biosynth (Pepscan), Pepticom Ltd., PeptiDream Inc., Bio-Synthesis Inc, CPC Scientific Inc., Circle Pharma, Zealand Pharma, and Chugai Pharmaceutical Co. Ltd.

Customization Scope

Free customization report with the procurement of the report, Modifications to the regional and segment scope. Particular Geographic competitive landscape.

Pricing and Available Payment Methods

Explore pricing alternatives that are customized to your particular study requirements.

Chapter 1. Methodology and Scope
1.1. Research Methodology
1.2. Research Scope & Assumptions

Chapter 2. Executive Summary

Chapter 3. Global Constrained Peptide Drug Market Snapshot

Chapter 4. Global Constrained Peptide Drug Market Variables, Trends & Scope
4.1. Market Segmentation & Scope
4.2. Drivers
4.3. Challenges
4.4. Trends
4.5. Investment and Funding Analysis of Metaverse Industry
4.6. Industry Analysis – Porter’s Five Forces Analysis
4.7. COVID-19 Impact on Metaverse Industry

Chapter 5. Market Segmentation 1: By Peptide Type Estimates & Trend Analysis
5.1. By Peptide Type & Market Share, 2019-2031
5.2. Market Size (Value US$ Mn) & Forecasts and Trend Analyses, 2022 to 2031 for the following By Peptide Type:

5.2.1. Disulfide-Rich Peptides (DRPs)
5.2.2. Cyclic Peptides

Chapter 6. Market Segmentation 2: By Potential Product Estimates & Trend Analysis
6.1. By Peptide Type & Market Share, 2019-2031
6.2. Market Size (Value US$ Mn) & Forecasts and Trend Analyses, 2022 to 2031 for the following By Potential Product:

6.2.1. BT5528
6.2.2. Rusfertide (PTG-300)
6.2.3. PN-943
6.2.4. PN-235
6.2.5. Zilucoplan (RA101495)

Chapter 7. Constrained Peptide Drug Market Segmentation 3: Regional Estimates & Trend Analysis

7.1. North America

7.1.1. North America Constrained Peptide Drug Market revenue (US$ Million) estimates and forecasts By Peptide Type, 2023-2031
7.1.2. North America Constrained Peptide Drug Market revenue (US$ Million) estimates and forecasts By Potential Product, 2023-2031
7.1.3. North America Constrained Peptide Drug Market revenue (US$ Million) estimates and forecasts by country, 2023-2031

7.1.3.1. U.S.
7.1.3.2. Canada

7.2. Europe

7.2.1. Europe Constrained Peptide Drug Market revenue (US$ Million) by By Peptide Type, 2023-2031
7.2.2. Europe Constrained Peptide Drug Market revenue (US$ Million) estimates and forecasts By Potential Product, 2023-2031
7.2.3. Europe Constrained Peptide Drug Market revenue (US$ Million) by country, 2023-2031

7.2.3.1. Germany
7.2.3.2. Poland
7.2.3.3. France
7.2.3.4. Italy
7.2.3.5. Spain
7.2.3.6. UK
7.2.3.7. Rest of Europe

7.3. Asia Pacific

7.3.1. Asia Pacific Constrained Peptide Drug Market revenue (US$ Million) by By Peptide Type, 2023-2031
7.3.2. Asia Pacific Constrained Peptide Drug Market revenue (US$ Million) estimates and forecasts By Potential Product, 2023-2031
7.3.3. Asia Pacific Constrained Peptide Drug Market revenue (US$ Million) by country, 2023-2031

7.3.3.1. China
7.3.3.2. India
7.3.3.3. Japan
7.3.3.4. Australia
7.3.3.5. Rest of Asia Pacific

7.4. Latin America

7.4.1. Latin America Constrained Peptide Drug Market revenue (US$ Million) by By Peptide Type, 2023-2031
7.4.2. Latin America Constrained Peptide Drug Market revenue (US$ Million) estimates and forecasts By Potential Product, 2023-2031
7.4.3. Latin America Constrained Peptide Drug Market revenue (US$ Million) by country, (US$ Million) 2023-2031

7.4.3.1. Brazil
7.4.3.2. Rest of Latin America

7.5. Middle East & Africa

7.5.1. Middle East & Africa Constrained Peptide Drug Market revenue (US$ Million) by By Peptide Type, (US$ Million)
7.5.2. Middle East & Africa Constrained Peptide Drug Market revenue (US$ Million) estimates and forecasts By Potential Product, 2023-2031
7.5.3. Middle East & Africa Constrained Peptide Drug Market revenue (US$ Million) by country, (US$ Million) 2023-2031

7.5.3.1. South Africa
7.5.3.2. GCC Countries
7.5.3.3. Rest of MEA

Chapter 8. Competitive Landscape

8.1. Major Mergers and Acquisitions/Strategic Alliances

8.2. Company Profiles


8.2.1. Aileron Therapeutics, Inc.
8.2.2. Bicycle Therapeutics plc
8.2.3. Spexis AG
8.2.4. Protagonist Therapeutics Inc.
8.2.5. Santhera Pharmaceuticals
8.2.6. Union Chimique Belge S.A. (UCB)
8.2.7. Creative Peptides
8.2.8. Biosynth (Pepscan)
8.2.9. Pepticom Ltd.
8.2.10. PeptiDream, Inc.
8.2.11. Bio-Synthesis Inc
8.2.12. CPC Scientific Inc.
8.2.13. Circle Pharma
8.2.14. Zealand Pharma
8.2.15. Chugai Pharmaceutical Co., Ltd.

Segmentation of Constrained Peptide Drugs Market-

Constrained Peptide Drugs Market By Peptide Type-

  • Disulfide-Rich Peptides (DRPs)
  • Cyclic Peptides

Constrained Peptide Drugs Market

Constrained Peptide Drugs Market By Potential Product-

  • BT5528
  • Rusfertide (PTG-300)
  • PN-943
  • PN-235
  • Zilucoplan (RA101495)

Constrained Peptide Drugs Market By Region-

North America-

  • The US
  • Canada
  • Mexico

Europe-

  • Germany
  • The UK
  • France
  • Italy
  • Spain
  • Rest of Europe

Asia-Pacific-

  • China
  • Japan
  • India
  • South Korea
  • South East Asia
  • Rest of Asia Pacific

Latin America-

  • Brazil
  • Argentina
  • Rest of Latin America

 Middle East & Africa-

  • GCC Countries
  • South Africa
  • Rest of Middle East and Africa

 InsightAce Analytic follows a standard and comprehensive market research methodology focused on offering the most accurate and precise market insights. The methods followed for all our market research studies include three significant steps – primary research, secondary research, and data modeling and analysis - to derive the current market size and forecast it over the forecast period. In this study, these three steps were used iteratively to generate valid data points (minimum deviation), which were cross-validated through multiple approaches mentioned below in the data modeling section.

Through secondary research methods, information on the market under study, its peer, and the parent market was collected. This information was then entered into data models. The resulted data points and insights were then validated by primary participants.

Based on additional insights from these primary participants, more directional efforts were put into doing secondary research and optimize data models. This process was repeated till all data models used in the study produced similar results (with minimum deviation). This way, this iterative process was able to generate the most accurate market numbers and qualitative insights.

Secondary research

The secondary research sources that are typically mentioned to include, but are not limited to:

  • Company websites, financial reports, annual reports, investor presentations, broker reports, and SEC filings.
  • External and internal proprietary databases, regulatory databases, and relevant patent analysis
  • Statistical databases, National government documents, and market reports
  • Press releases, news articles, and webcasts specific to the companies operating in the market

The paid sources for secondary research like Factiva, OneSource, Hoovers, and Statista

Primary Research:

Primary research involves telephonic interviews, e-mail interactions, as well as face-to-face interviews for each market, category, segment, and subsegment across geographies

The contributors who typically take part in such a course include, but are not limited to: 

  • Industry participants: CEOs, CBO, CMO, VPs, marketing/ type managers, corporate strategy managers, and national sales managers, technical personnel, purchasing managers, resellers, and distributors.
  • Outside experts: Valuation experts, Investment bankers, research analysts specializing in specific markets
  • Key opinion leaders (KOLs) specializing in unique areas corresponding to various industry verticals
  • End-users: Vary mainly depending upon the market

Data Modeling and Analysis:

In the iterative process (mentioned above), data models received inputs from primary as well as secondary sources. But analysts working on these models were the key. They used their extensive knowledge and experience about industry and topic to make changes and fine-tuning these models as per the product/service under study.

The standard data models used while studying this market were the top-down and bottom-up approaches and the company shares analysis model. However, other methods were also used along with these – which were specific to the industry and product/service under study.

To know more about the research methodology used for this study, kindly contact us/click here.

This website is secure, and we do not share your personal information with any third party. Privacy Policy

Need specific information/chapter from the report of the custom data table, graph or complete report? Tell us more.

Frequently Asked Questions

How big is the Constrained Peptide Drugs Market?

Constrained Peptide Drugs Market expected to grow at a 31.56% CAGR during the forecast period for 2023-2031

Aileron Therapeutics Inc., Bicycle Therapeutics plc, Spexis AG, Protagonist Therapeutics Inc., Santhera Pharmaceuticals, Union Chimique Belge S.A. (UC

Our Clients

Media Citations

Growth opportunities and latent adjacency in Pharmaceuticals

Select Licence Type
$4456
$7786
$10000
$1200
Get a Custom Report
Contact us with a specific research request.

Kindly share us with a topic or product segment or objectives to meet your strategy goals

Review Request

We’ll review your request & send a personalized quote for cost and time needed

Final Delivery

Sit back while our team work on your research. We will send bi-monthly updates and discuss our finding on a conference call upon final delivery..